Educational Stock Research Review: Eli Lilly and Company (LLY)
Welcome to this comprehensive educational research review of Eli Lilly and Company (LLY). This article is provided by StockValueFinder.com to help investors understand how to apply quantitative screening metrics to a real-world example. Rather than providing a simple "buy" or "sell" recommendation, this guide is designed to teach you how to evaluate a company's financial health, capital efficiency, and valuation using a standardized set of benchmarks.
Eli Lilly and Company operates within the Healthcare sector, specifically in the Drug Manufacturers – General industry. As a major player in the pharmaceutical space, the company is subject to rigorous regulatory environments and high research and development costs. To determine if a stock is a sound addition to a portfolio, we look beyond the brand name and examine the hard numbers.
Why the StockValueFinder Score Matters
The StockValueFinder system assigns a numerical score based on how many financial benchmarks a company passes. For Eli Lilly and Company (LLY), the current StockValueFinder score is 50%. Based on this score and the accompanying metrics, the current rating is AVOID.
A score of 50% indicates that the company passed exactly half of the primary financial health and valuation tests. In a disciplined value-investing framework, a high score (typically 80% or above) suggests a company that is simultaneously profitable, efficiently managed, conservatively leveraged, and reasonably priced. A score of 50% suggests a conflict between the company's operational performance and its current market price or debt structure.
Understanding this score is the first step in educational analysis: a company can be a "great business" (high operational efficiency) but a "poor stock" (too expensive to buy at current levels).
EPS Strength and Consistency
Earnings Per Share (EPS) is a critical metric because it tells us how much profit is allocated to each outstanding share of common stock. For long-term investors, consistency in EPS is often more important than a single year of explosive growth. Consistent earnings suggest a predictable business model and reliable management.
In the case of Eli Lilly and Company, the EPS test result is: Did not pass.
While detailed historical EPS figures were not supplied for this specific review, the system recorded a failure for this test. In a typical educational screen, a "Pass" requires the company to show steady or growing earnings over a multi-year period without significant volatile swings or deep losses.
For example, if Company A has EPS figures of $2.00, $2.10, and $2.20 over three years, it shows a consistent upward trend. If Company B has EPS figures of $5.00, -$1.00, and $3.00, it is considered inconsistent and would likely fail the EPS strength test. Because LLY did not pass this test, it suggests that its earnings history does not meet the strict consistency requirements of the StockValueFinder screen.
ROIC and Capital Efficiency
Return on Invested Capital (ROIC) is perhaps the most important metric for determining how well a management team allocates money. ROIC measures how much profit a company generates for every dollar of capital (debt and equity) it puts to work.
Eli Lilly and Company has an ROIC of 29.90%. This test result is: Passed.
StockValueFinder generally prefers an ROIC of 10% or higher. A high ROIC indicates that the company has a "moat" or a competitive advantage that allows it to generate superior returns on its investments.
To put this in perspective, consider two hypothetical companies
– Company X has an ROIC of 4%. This means for every $100 invested in the business, it only generates $4 in profit. This is a weak return that barely exceeds the cost of borrowing money. – Company Y has an ROIC of 15%. This means for every $100 invested, it generates $15 in profit. Company Y is significantly more efficient at creating value.
With an ROIC of 29.90%, Eli Lilly is operating well above the 10% threshold, demonstrating exceptional capital efficiency in its drug manufacturing operations.
Interest Coverage and Financial Safety
Interest coverage is a solvency ratio that describes how easily a company can pay interest on its outstanding debt. It is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expenses.
For Eli Lilly and Company, the interest coverage test result is: Passed.
StockValueFinder prefers an interest coverage ratio of 6 or higher. A high ratio means the company has a large cushion; even if earnings drop temporarily, the company can still meet its interest obligations without risking bankruptcy.
For example, if a company has an interest coverage of 2x, it only earns twice what it owes in interest. A slight dip in revenue could make it impossible to pay the bank. Conversely, a company with 8x coverage is in a much healthier position, as it earns eight times its interest obligations. By passing this test, LLY demonstrates that its current earnings are more than sufficient to cover its interest costs.
Debt Payback and Balance Sheet Discipline
While interest coverage tells us if a company can pay the *interest*, the debt payback metric tells us how long it would take the company to pay off its *entire* debt load using its current annual profits.
Eli Lilly and Company has a debt payback period of 4.56 years. This test result is: Did not pass.
StockValueFinder prefers a debt payback period of 3 years or less. This is a measure of balance sheet discipline. The shorter the payback period, the less risk the company faces from creditors and the more flexibility it has to weather an economic downturn.
Consider this comparison
– A company with a 1.5-year payback period is very conservative; it could clear its debts quickly if needed. – A company with a 7-year payback period is heavily leveraged; it is tied to its debt for a long duration, which increases financial risk.
At 4.56 years, LLY exceeds the 3-year preference, which is why the system marked this test as a failure.
P/E Ratio and Valuation Discipline
The Price-to-Earnings (P/E) ratio measures how much the market is willing to pay for every $1 of a company's earnings. It is the primary tool for determining if a stock is overvalued or undervalued.
Eli Lilly and Company has a P/E ratio of 43.03. The recent price is $1,288.30. This valuation test result is: Did not pass.
For valuation discipline, StockValueFinder prefers a P/E ratio of 15 or lower. A lower P/E generally indicates that the stock is "cheaper" relative to its earnings, providing a larger margin of safety for the investor.
For example, if Company A has a P/E of 8, you are paying $8 for every $1 of profit. If Company B has a P/E of 40, you are paying $40 for every $1 of profit. Assuming the business quality is similar, the company with the P/E of 8 is more value-oriented.
With a P/E of 43.03, LLY is trading at a significant premium. This suggests that the market has already priced in a great deal of future growth, leaving little room for error and reducing the "value" appeal of the stock.
Moving Average Trend and Entry Timing
While the metrics above focus on the "what" (the value of the company), the moving average signal focuses on the "when" (the timing of the trade). Trend analysis is used for timing discipline; it is not a guarantee that the stock must rise, but rather an observation of current momentum.
Eli Lilly and Company currently shows a Moving Average Signal of: STRONG BUY TREND.
However, it is important to note the following
– Entry signal: N/A – Entry status: N/A – Limit buy idea: N/A – Pullback zone: N/A – Risk stop / trend risk level: N/A
In a complete technical setup, an investor would look for a "pullback zone"—a price range where the stock dips slightly while remaining in an uptrend—to enter the position. Because these values are N/A, the system is not providing a specific educational entry point at this time. The "Strong Buy Trend" indicates that the price has been moving upward, but without a specific entry signal or risk stop, the timing remains undefined.
Overall Financial Strengths and Weaknesses
To summarize the educational findings for LLY, we can divide the results into operational strengths and valuation/structural weaknesses.
**Strengths:** – **Capital Efficiency:** The ROIC of 29.90% is a standout figure, showing that the company is highly effective at turning invested capital into profit. – **Short-term Solvency:** Passing the interest coverage test indicates that the company is not in immediate danger of defaulting on its interest payments. – **Market Momentum:** The "Strong Buy Trend" shows that the stock currently has positive price momentum.
**Weaknesses:** – **Valuation:** A P/E of 43.03 is nearly three times the preferred threshold of 15, suggesting the stock is expensive. – **Debt Duration:** A debt payback period of 4.56 years exceeds the preferred 3-year limit. – **Earnings Consistency:** The failure of the EPS test suggests a lack of the steady, predictable growth pattern preferred by the StockValueFinder screen.
Risks and Limitations
When analyzing a healthcare company like Eli Lilly, investors must consider that high ROIC and strong trends can be offset by valuation risks. When a stock has a P/E ratio as high as 43.03, any slight miss in earnings or a regulatory setback can lead to a sharp price correction, as the "premium" price is based on high expectations.
Furthermore, the failure of the debt payback and EPS tests indicates that the company's financial structure is not as conservative as the StockValueFinder ideal. While the company is currently profitable and solvent, it does not meet the strict "Value" criteria used to identify low-risk, high-reward opportunities.
Educational Conclusion
Eli Lilly and Company (LLY) presents a classic case study in the difference between a high-performing business and a high-value stock. Operationally, the company is very strong, as evidenced by its 29.90% ROIC and its ability to cover interest payments. However, from a value-investing perspective, the stock fails on several key fronts: it is expensive (P/E 43.03), its debt payback is slower than preferred (4.56 years), and its EPS consistency did not pass the screen.
This is why the StockValueFinder score is 50% and the rating is AVOID. The system is not saying the company is "bad," but rather that the current price does not offer a disciplined entry point based on the supplied metrics. For a student of investing, LLY serves as a reminder that even a company with a "Strong Buy Trend" can be an unattractive investment if the valuation is too high and the balance sheet is not sufficiently conservative.
This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.
Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings
Specializing in global financial markets, macroeconomic trends, and equity valuation, Omar Gemani brings a disciplined, research-driven perspective to investment analysis. His editorial approach emphasizes company fundamentals, earnings sustainability, financial strength, and long-term growth potential. Combining fundamental analysis with broader economic indicators, Omar evaluates investment opportunities while highlighting market uncertainty, valuation risks, and the importance of capital preservation.